S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

PURE Bioscience Stock Forecast, Price & News

-0.03 (-3.82 %)
(As of 01/22/2021 12:00 AM ET)
Today's Range
Now: $0.76
50-Day Range
MA: $0.83
52-Week Range
Now: $0.76
Volume15,949 shs
Average Volume54,085 shs
Market Capitalization$65.85 million
P/E Ratio37.77
Dividend YieldN/A
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. It manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection and formulates with other compounds. The company offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. It also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÃRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. The company was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.
PURE Bioscience logo


Overall MarketRank

0.67 out of 5 stars

Medical Sector

1223rd out of 1,923 stocks

Miscellaneous Chemical Products Industry

11th out of 15 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Miscellaneous chemical products
Current SymbolOTCMKTS:PURE



Sales & Book Value

Annual Sales$6.92 million
Cash Flow$0.00 per share
Book Value$0.06 per share



Market Cap$65.85 million
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable
-0.03 (-3.82 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PURE News and Ratings via Email

Sign-up to receive the latest news and ratings for PURE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

PURE Bioscience (OTCMKTS:PURE) Frequently Asked Questions

How has PURE Bioscience's stock price been impacted by Coronavirus (COVID-19)?

PURE Bioscience's stock was trading at $0.5389 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PURE shares have increased by 40.1% and is now trading at $0.7550.
View which stocks have been most impacted by COVID-19

What stocks does MarketBeat like better than PURE Bioscience?

Wall Street analysts have given PURE Bioscience a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PURE Bioscience wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is PURE Bioscience's next earnings date?

PURE Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for PURE Bioscience

How were PURE Bioscience's earnings last quarter?

PURE Bioscience, Inc. (OTCMKTS:PURE) announced its quarterly earnings data on Thursday, March, 12th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $0.35 million for the quarter. PURE Bioscience had a return on equity of 27.62% and a net margin of 11.70%.
View PURE Bioscience's earnings history

Who are some of PURE Bioscience's key competitors?

What other stocks do shareholders of PURE Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PURE Bioscience investors own include NVIDIA (NVDA), The Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), Riot Blockchain (RIOT), Enphase Energy (ENPH), Mastercard (MA), Main Street Capital (MAIN), Twilio (TWLO) and (CGC).

Who are PURE Bioscience's key executives?

PURE Bioscience's management team includes the following people:
  • Mr. Tom Y. Lee, CEO, Pres & Chairman (Age 71, Pay $46k)
  • Mr. Mark Stuart Elliott, VP of Fin. and Principal Financial & Accounting Officer (Age 45, Pay $125k)
  • Mr. Thomas Richard Myers, Chief Operating Officer (Age 68, Pay $200k)
  • Ms. Bridget C. Tinsley-Cormier M.S., Sr. VP of Technology & Bus. Devel. and VP of Market Devel.

What is PURE Bioscience's stock symbol?

PURE Bioscience trades on the OTCMKTS under the ticker symbol "PURE."

How do I buy shares of PURE Bioscience?

Shares of PURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PURE Bioscience's stock price today?

One share of PURE stock can currently be purchased for approximately $0.76.

How big of a company is PURE Bioscience?

PURE Bioscience has a market capitalization of $65.85 million and generates $6.92 million in revenue each year. PURE Bioscience employs 10 workers across the globe.

What is PURE Bioscience's official website?

The official website for PURE Bioscience is www.purebio.com.

How can I contact PURE Bioscience?

PURE Bioscience's mailing address is 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 619-596-8600 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.